Natural Endocannabinoid Derivatives as Templates for the Development of FAAH Inhibitors
Letters in Drug Design & Discovery2005Vol. 2(5), pp. 372–376
Related Papers
- → Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system(2003)301 cited
- → Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide11Abbreviations: AEA, anandamide, arachidonyl ethanolamide; PEA, palmitoylethanolamide, N-(2-hydroxyethyl) hexadecamide; FAAH, fatty acid amide hydrolase; CB, cannabinoid; PMSF, phenylmethylsulfonyl fluoride; MAFP, methyl arachidonyl fluorophosphonate; methAEA, arachidonyl-1′-hydroxy-2′-propylamide; and NSAIDs, nonsteroidal anti-inflammatory drugs.(2001)128 cited
- → Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide—targets for drug development?(2002)69 cited
- → Natural Endocannabinoid Derivatives as Templates for the Development of FAAH Inhibitors(2005)
- → Fatty acid amide hydrolase, anandamide, and neurological diseases(2023)